Treatment of Abnormal Excessive Vaginal Discharge by Unani medicine Sailani

Clinical Validation of Unani Pharmacopoeial Formulation Sailani in SayalÄ?n al-Rahim (Abnormal Excessive Vaginal Discharge)

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2020/02/023428

Enrollment

300

Registered

2020-02-19

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: - Health Condition 2: N899- Noninflammatory disorder of vagina, unspecified

Interventions

Intervention1: Sailani: 2 tablets orally twice daily to be taken with lukewarm water after meals for two weeks Control Intervention1: NIL: NIL

Eligibility

Inclusion criteria

Inclusion criteria: 1. Sexually active women of age group 18 â?? 45 years. 2.All women complaining of vaginal discharge. 3.Associated symptoms: I. Vulval Itching II. Low Backache III. Generalised weakness IV. Burning Micturition V. Abnormal vaginal odour 4.Patients willing to take part in study.

Exclusion criteria

Exclusion criteria: 1. Patient more than 45 years of age. 2. Menopausal, Pregnant and Lactating women. 3. Known cases of any systemic illness like hypertension, diabetes mellitus. 4. Patients with H/O fibroid, polyp, ovarian tumour or cyst, uterine-prolaps and malignancy. 5. Patients using OCPs or intrauterine devices. 6. Known cases of HIV, Syphilis, Gonorrhoea. 7. Patients having acute/acute-on chronic/Chronic PID as per CDC Criteria

Design outcomes

Primary

Measure	Time frame
Improvement in signs and symptoms of SayalÄ?n al-Rahim (Abnormal Excessive Vaginal Discharge)Timepoint: 4 weeks	—

Secondary

Measure	Time frame
Haematological and biochemical assessment for safety assessmentTimepoint: Investigations will be done at baseline and end of treatment	—

Countries

India

Contacts

Public ContactDr Pradeep Kumar

Central Council for Research in Unani Medicine (CCRUM)

ccrum507@rediffmail.com9213511298

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026